Octave Specialty (OSG) EBITDA (2010 - 2026)

Octave Specialty's EBITDA history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, EBITDA fell 16.34% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was -$218.5 million, a 1704.25% decrease from a year earlier, with the FY2025 full-year figure at -$332.2 million, down 2399.26% from the prior year.
• EBITDA rose to $2.4 million in Q1 2026 per OSG's latest filing, from -$226.2 million in the prior quarter.
• Across five years, EBITDA topped out at $11.0 million in Q3 2022 and bottomed at -$226.2 million in Q4 2025.
• The 5-year median for EBITDA is $3.5 million (2024), against an average of -$10.7 million.
• Across the five-year window, EBITDA soared 114.41% in 2023 and slumped 6458.64% in 2025, its largest moves.
• Year by year, EBITDA stood at $10.5 million in 2022, then plunged by 65.84% to $3.6 million in 2023, then decreased by 0.86% to $3.6 million in 2024, then slumped by 6458.64% to -$226.2 million in 2025, then surged by 101.04% to $2.4 million in 2026.
• Per Business Quant, the three latest OSG EBITDA figures stand at $2.4 million (Q1 2026), -$226.2 million (Q4 2025), and $2.7 million (Q3 2025).